Gestational diabetes & diabetes in pregnancy
Metformin safety during pregnancy in women with gestational diabetes mellitus: A systematic review and meta‐analysis of maternal, neonatal and long‐term outcomes
Authors' conclusion
Metformin appears safe and effective in GDM management, but more data are needed on long-term outcomes.
Study context
- Population
- Women with gestational diabetes mellitus (GDM) requiring pharmacological therapy; Randomized controlled trials (RCTs) and follow-up studies, PubMed and Embase to 29 August 202410 RCTs
- Comparison
- Metformin vs insulin in GDM
- Outcome
- Neonatal hypoglycaemia, birthweight and long-term metabolic outcomes
Methodological detailsIVhet model, RoB 2.0 and ROBINS-I quality assessment
- IVhet model
- RoB 2.0 and ROBINS-I quality assessment
Pooled result
As reported in the abstract
Neonatal hypoglycaemia; birthweight
Metformin vs InsulinOdds ratio (95% CI)
Neonatal hypoglycaemia; significant reduction
0.65(0.46–0.92)
Metformin vs InsulinMD, g (95% CI)
Birthweight; lower with metformin
−68.96(−108.34 to −29.57)
Further pooled results
- Non-significant trend towards reduced LGA risk with metformin
Original publication
Metformin safety during pregnancy in women with gestational diabetes mellitus: A systematic review and meta‐analysis of maternal, neonatal and long‐term outcomes. Diabet Med. Published 7 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →